Jounce Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€70.36M - Cost of goods sold
€0.00 - Gross profit
€70.36M - SG&A expenses
€26.57M - R&D expenses
€88.61M - EBITDA
-€43.03M - D&A
€1.79M - EBIT
-€44.82M - Interest expenses
€0.00 - EBT
-€43.57M - Tax expenses
€115.83K - Net income
-€43.69M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€686.40K - Changes in working capital
€7.62M - Operating cash flow
-€24.78M - Capex
€788.50K - Other investing cash flow
€0.00 - Net investing cash flow
€71.62M - Total cash dividends paid
€0.00 - Issuance of common stock
€379.24K - Debt repayment
€0.00 - Other financing cash flow
€0.00 - Net financing cash flow
€379.24K - Foreign exchange effects
€0.00 - Net change in cash
€47.23M - Cash at end of period
€130.28M - Free cash flow
-€23.99M
Balance sheet
- Cash and cash equivalents
€129.19M - Cash and short-term investments
€162.63M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€6.60M - Total current assets
€169.22M - Property, plant & equipment
€10.57M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€2.58M - Total non-current assets
€13.14M - Total assets
€182.37M - Accounts payable
€1.80M - Short-term debt
€3.56M - Other current liabilities
€14.86M - Total current liabilities
€20.22M - Long-term debt
€5.04M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€5.04M - Total liabilities
€25.26M - Common stock
€43.76K - Retained earnings
-€251.22M - Other equity
-€580.87K - Total equity
€157.11M - Total liabilities and shareholders' equity
€182.37M
Company information
- Market capitalization
€84.40M - Employees
141 - Enterprise Value
-€41.60M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -2,530,903,196,224.8% - EBITDA margin
-
-61.2% Much better than peer group: -5,986,852,853,023.2% - EBIT margin
-
-63.7% Much better than peer group: -6,330,848,341,319.7% - EBT margin
-
-61.9% Much better than peer group: -6,075,178,515,081.1% - Net margin
-
-62.1% Much better than peer group: -6,075,178,517,647.0% - ROE
-
-27.8% Much better than peer group: -96.8% - ROA
-
-24.0% Much better than peer group: -51.6% - Asset turnover
-
38.6% Much better than peer group: -1,733.7% - FCF margin
-
-36.3% Much better than peer group: -5,061,251,661,339.1% - FCF yield
-30.3% - Efficiency ratio
161.2% - Net sales per employee
-
€498.98K - Net income per employee
-
-€309.85K